Buparlisib (BUP) or placebo (PBO) plus fulvestrant (FUL) in postmenopausal patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): Overall survival (OS) results from BELLE-2, a randomized, phase III study Meeting Abstract
| Authors: | Campone, M.; Im, S. A.; Iwata, H.; Clemons, M.; Ito, Y.; Awada, A.; Chia, S.; Jagiełło-Gruszfeld, A.; Pistilli, B.; Tseng, L. M.; Hurvitz, S.; Masuda, N.; Cortés, J.; De Laurentiis, M.; Arteaga, C. L.; Jiang, Z.; Jonat, W.; Sellami, D.; El-Hashimy, M.; Le Mouhaër, S.; Sankaran, B.; Bourdeau, L.; Baselga, J. |
| Abstract Title: | Buparlisib (BUP) or placebo (PBO) plus fulvestrant (FUL) in postmenopausal patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): Overall survival (OS) results from BELLE-2, a randomized, phase III study |
| Meeting Title: | 40th Annual San Antonio Breast Cancer Symposium (SABCS 2017) |
| Journal Title: | Cancer Research |
| Volume: | 78 |
| Issue: | 4 Suppl. |
| Meeting Dates: | 2017 Dec 5-9 |
| Meeting Location: | San Antonio, TX |
| ISSN: | 0008-5472 |
| Publisher: | American Association for Cancer Research |
| Date Published: | 2018-02-01 |
| Language: | English |
| ACCESSION: | WOS:000425489402271 |
| PROVIDER: | wos |
| DOI: | 10.1158/1538-7445.SABCS17-PD5-12 |
| Notes: | Meeting Abstract: PD5-12 -- Source: Wos |
